Literature DB >> 2066398

Malignant glioma modulation of immune function: relative contribution of different soluble factors.

W T Couldwell1, P Dore-Duffy, M L Apuzzo, J P Antel.   

Abstract

We analyzed a series of human glioma cell lines with regard to establishing what variables may contribute to their overall functional immunomodulating capability. We observed that supernatants derived from the gliomas, but not those from non-malignant human astrocyte cultures, suppressed lymphocyte proliferation. The extent of suppression elicited differed between tumors and for the same tumor depending upon its growth phase. For individual gliomas, supernatants from cultures approaching or at confluency elicited maximal lymphocyte suppression. For the series of tumors, levels of production of the immunosuppressive molecules transforming growth factor beta 2 and prostanoids (prostaglandin E2) did not correlate with the levels of functional suppression observed at any of the different growth phases. In some cases, glioma cultures grown in the presence of indomethacin to abolish prostanoid synthesis resulted in supernatants with net stimulatory activity. Our results indicate that malignant transformation of astrocytes is associated with acquisition of immunosuppressive capability which is determined by the combined effect of multiple immunomodulatory soluble factors, inhibitory or enhancing, and is dependent on the growth phase of the tumor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2066398     DOI: 10.1016/0165-5728(91)90052-9

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  11 in total

Review 1.  Combining cytotoxic and immune-mediated gene therapy to treat brain tumors.

Authors:  James F Curtin; Gwendalyn D King; Marianela Candolfi; Remy B Greeno; Kurt M Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Top Med Chem       Date:  2005       Impact factor: 3.295

Review 2.  Immunotherapy for solid tumors--a review for surgeons.

Authors:  Abdul Saied; Venu G Pillarisetty; Steven C Katz
Journal:  J Surg Res       Date:  2013-12-25       Impact factor: 2.192

3.  Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma.

Authors:  Thomas Schneider; Michael Sailer; Siegfried Ansorge; Raimund Firsching; Dirk Reinhold
Journal:  J Neurooncol       Date:  2006-04-14       Impact factor: 4.130

4.  The alteration of prostaglandin E2 levels in patients with brain tumors before and after tumor removal.

Authors:  Joon-Khim Loh; Shiuh-Lin Hwang; Ann-Shung Lieu; Tzuu-Yuan Huang; Shen-Long Howng
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

Review 5.  Overview of cellular immunotherapy for patients with glioblastoma.

Authors:  Elodie Vauleon; Tony Avril; Brigitte Collet; Jean Mosser; Véronique Quillien
Journal:  Clin Dev Immunol       Date:  2010-10-04

6.  Suppression of high affinity IL-2 receptors on mitogen activated lymphocytes by glioma-derived suppressor factor.

Authors:  L H Elliott; W H Brooks; T L Roszman
Journal:  J Neurooncol       Date:  1992-09       Impact factor: 4.130

Review 7.  Immunotherapeutic approaches for glioma.

Authors:  Hideho Okada; Gary Kohanbash; Xinmei Zhu; Edward R Kastenhuber; Aki Hoji; Ryo Ueda; Mitsugu Fujita
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

8.  Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo.

Authors:  Timothy F Witham; Lorissa Villa; Tianbing Yang; Ian F Pollack; Hideho Okada; Paul D Robbins; William H Chambers
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

9.  U87MG glioma cells overexpressing IL-17 acclerate early-stage growth in vivo and cause a higher level of CD31 mRNA expression in tumor tissues.

Authors:  Jinhui Hu; Hongxing Ye; Denghai Zhang; Weiwei Liu; Min Li; Ying Mao; Yuan Lu
Journal:  Oncol Lett       Date:  2013-08-07       Impact factor: 2.967

Review 10.  Immune Evasion Strategies of Glioblastoma.

Authors:  Seyed-Mostafa Razavi; Karen E Lee; Benjamin E Jin; Parvir S Aujla; Sharareh Gholamin; Gordon Li
Journal:  Front Surg       Date:  2016-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.